Summit Therapeutics: World Lung Data Not Enough For Ivonescimab To Unseat Keytruda (Yet)

0


Dog in window

Michal Krakowiak/E+ via Getty Images

Topline Summary and Update

When I last wrote about Summit Therapeutics (NASDAQ:SMMT) back around the time of ASCO 2024, I was excited about the prospects of their heir apparent bispecific approach to combination

Ivonescimab (n = 198) Pembrolizumab (HARMONi-2) (n = 200) Pembrolizumab (KEYNOTE-024) (n = 154) Pembro + chemo (KEYNOTE-189) (n = 410)
Median PFS 11.14 5.82 10.3 8.8

Leave a Reply

Your email address will not be published. Required fields are marked *